Cannabis Stock Tilray (TLRY) Strengthens Executive Leadership Team with the Appointment of Andrew Pucher as CCDO

Tilray (TLRY) announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer (CCDO). In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy. Andrew joins Tilray from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs’ Global Healthcare Investment Banking Group in New York, where he advised on[…]

Read more

General Electric’s (GE) “Teach-In” Boosts Investor Confidence; RBC Weighs in on the Stock

Last week, General Electric (GE) hosted what it dubbed as a “teach-in” for investors and analysts to learn about its insurance business. In an effort to show more transparency in its restructuring efforts, CEO Larry Culp hosted this event to discuss what the company is doing with its insurance business and allow for analysts to critique and ask questions. RBC analyst Deane Dray says the company’s assumptions are reasonable with no new negatives, and does not change the picture on the stock moving forward. The analyst maintains his Outperform rating and $12 price target on the stock, which implies nearly[…]

Read more

Cannabis Stock Tilray (TLRY) Goes Negative for the Year; Here’s Why

It’s been two weeks since Jefferies analyst Owen Bennett initiated coverage of Aurora Cannabis (ACB) a “buy” rating, arguing the company is priced attractively relative to its two closest rivals in Canadian cannabis stocks, Canopy Growth (CGC) and Tilray (TLRY). On Friday, Bennett took the next logical step — and initiated Tilray at “underperform,” with a $61 price target, which implies nearly 13% downside from current levels. In reaction, Tilray shares tumbled nearly 8% to $69.72, leaving the stock in negative territory in 2019. Now, it’s not that Bennett thinks Tilray is utterly without hope. To the contrary, the analyst had[…]

Read more